Sterling Capital Management’s Corcept Therapeutics CORT Stock Holding History

Sterling Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.4K	Sell	626 -47	-7%	-$2.84K	﹤0.01%	1564
2026 Q1	$27.1K	Hold	673	–	–	﹤0.01%	1882
2025 Q4	$23.4K	Buy	673 +530	+371%	+$41.6K	﹤0.01%	2140
2025 Q3	$11.9K	Sell	143 -1	-0.7%	-$72	﹤0.01%	2395
2025 Q2	$10.6K	Buy	144 +59	+69%	+$4.28K	﹤0.01%	2099
2025 Q1	$9.71K	Buy	85 +2	+2%	+$122	﹤0.01%	1872
2024 Q4	$4.18K	Hold	83	–	–	﹤0.01%	2538
2024 Q3	$3.84K	Buy	+83	New	+$2.95K	﹤0.01%	1862
2019 Q3	$1.17M	Buy	+82,895	New	+$1.02M	0.01%	553

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's CORT Position: Q2 2026 in Review

Sterling Capital Management reduced its Corcept Therapeutics (CORT) stake by 7% in Q2 2026, selling an estimated $2.84K and leaving 626 shares worth $54.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1564.

Sterling Capital Management first reported a position in CORT in Q3 2019 and has held it in 9 quarters since. The position peaked at $1.17M in Q3 2019. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Sterling Capital Management held 626 shares of Corcept Therapeutics worth $54.4K as of Q2 2026.
Sterling Capital Management sold 47 Corcept Therapeutics shares in Q2 2026, an estimated $2.84K.
Corcept Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1564 holding.
Sterling Capital Management first reported a position in Corcept Therapeutics in Q3 2019 and has held it in 9 quarters since.
Sterling Capital Management's Corcept Therapeutics position peaked at $1.17M in Q3 2019.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.